GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Liabilities-to-Assets

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Liabilities-to-Assets : 109.03 (As of Sep. 2015)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. OncoVista Innovative Therapies's Total Liabilities for the quarter that ended in Sep. 2015 was $6.65 Mil. OncoVista Innovative Therapies's Total Assets for the quarter that ended in Sep. 2015 was $0.06 Mil. Therefore, OncoVista Innovative Therapies's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2015 was 109.03.


OncoVista Innovative Therapies Liabilities-to-Assets Historical Data

The historical data trend for OncoVista Innovative Therapies's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Liabilities-to-Assets Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 1.06 3.92 33.50 436.62

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.39 436.62 107.09 252.32 109.03

Competitive Comparison of OncoVista Innovative Therapies's Liabilities-to-Assets

For the Biotechnology subindustry, OncoVista Innovative Therapies's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Liabilities-to-Assets falls into.



OncoVista Innovative Therapies Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

OncoVista Innovative Therapies's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2014 is calculated as:

Liabilities-to-Assets (A: Dec. 2014 )=Total Liabilities/Total Assets
=5.676/0.013
=436.62

OncoVista Innovative Therapies's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2015 is calculated as

Liabilities-to-Assets (Q: Sep. 2015 )=Total Liabilities/Total Assets
=6.651/0.061
=109.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoVista Innovative Therapies  (OTCPK:OVIT) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


OncoVista Innovative Therapies Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines